US biotech Biogen has entered into a definitive agreement to acquire Massachusetts-based Alcyone Therapeutics, a company the ...

South Korean biotech CorestemChemon (Kosdaq: 166480) has shared Phase III ALSummit trial findings for its autologous stem ...

Portuguese venture firm Biovance Capital Partners has led a series A financing for Mondego Bio, joined by US investors ...

US biotech Arvinas today provided an update on its 2021 collaboration with pharma giant Pfizer for the co-development of ...

California, USA-based liver specialist 89bio saw its shares rocket more than 83% to $14.83 in pre-market activity on the news ...

China’s Mabwell (688062.SH) and Californian biotech venture firm Aditum Bio have combined to launch Kalexo Bio.

The European Commission (EC) has granted marketing authorization for US biotech major Biogen’s Zurzuvae (zuranolone) to treat ...

Regeneron Pharmaceuticals has announced the primary endpoint was met in the Phase III OPTIMA trial investigating garetosmab ...

The biologics supply chain has shifted from a technical backwater into a political and regulatory battleground. Vectors, ...

The European Court of Auditors has warned that Europe still lacks a reliable system to prevent and manage medicine shortages, ...

US drugmaker Eli Lilly’s battle for dominance of the GLP-1 weight loss and diabetes market with Novo Nordisk is becoming an epic.

Deciphera, a subsidiary of Japan’s Ono Pharmaceutical, has received approval from the European Commission (EC) for Romvimza (vimseltinib) for the treatment of adult patients with symptomatic ...